Merck Begins Phase 3 Trial Of MK-1084 As First-Line Treatment Of Certain Metastatic NSCLC Patients
4/4 13:12
(RTTNews) - Merck & Co. Inc. (MRK), known as MSD outside of the U.S. and Canada, announced Thursday it has initiated a Phase 3 clinical trial evaluating MK-1084, an investigational oral selective KRAS G12C inhibitor, in combination with KEYTRUDA for the first-line treatment of ce...